Mitotane
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mitotane |
| DrugBank ID | DB00648 |
| Brand Names (EU) | Lysodren |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.05% |
Approved Indication (EMA)
Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | multiple endocrine neoplasia | 98.05% | DL |
| 2 | acne (disease) | 97.76% | DL |
| 3 | breast fibrocystic disease | 93.76% | DL |
| 4 | benign mammary dysplasia | 93.03% | DL |
| 5 | seborrheic keratosis | 92.99% | DL |
| 6 | vulvar inverted follicular keratosis | 92.70% | DL |
| 7 | apocrine adenosis of breast | 91.84% | DL |
| 8 | blunt duct adenosis of breast | 91.84% | DL |
| 9 | fat necrosis of breast | 90.18% | DL |
| 10 | breast abscess | 90.18% | DL |
| 11 | motor nerve neuritis | 89.38% | DL |
| 12 | vestibular neuronitis | 89.29% | DL |
| 13 | brachial plexus neuritis | 88.98% | DL |
| 14 | lactation disease | 88.38% | DL |
| 15 | neuroretinitis | 85.49% | DL |
| 16 | breast adenosis | 84.98% | DL |
| 17 | familial pityriasis rubra pilaris | 81.62% | DL |
| 18 | candidiasis | 81.54% | DL |
| 19 | inherited cutis laxa | 79.13% | DL |
| 20 | alkaptonuria | 77.89% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.